Daiichi Life Group, Inc. (8750.T) fair value

ACCE thesis

Daiichi Life Group writes individual life, annuity and health insurance across Japan and, through its overseas subsidiaries, in Asia and the US, distributing mainly through its own sales force and agency channels. The moat is distribution depth and a balance sheet that lets it absorb the long-duration liabilities these products create, which matters more as Japan's policy rate rises and reprices the bond book. Revenue growth of 28.0% is the number to interrogate first, since it likely reflects investment income and policy-reserve accounting rather than a step-change in premium volume, and a PM should confirm that before reading it as operating momentum. At a trailing P/E of 11.9 and a forward P/E of 4.9, the market is pricing either a sharp earnings decline or a skeptical view of how durable the current earnings base is, and the gap between those multiples is the first thing to test. With a 13.6% ROE and a 16.7% operating margin at a 6.57 trillion yen market cap, the stock is not in the index universe we screen, which makes it a candidate for a deeper look only if the forward earnings estimates hold up under scrutiny.